Department of Pharmacology, I.S.F College of Pharmacy, Moga, 142001, Punjab, India.
Department of Pharmacology, School of Pharmaceutical Sciences, CT University, Ludhiana, Punjab, India.
Inflamm Res. 2018 May;67(5):391-405. doi: 10.1007/s00011-018-1129-8. Epub 2018 Jan 25.
Vascular endothelium plays a role in capillary transport of nutrients and drugs and regulates angiogenesis, homeostasis, as well as vascular tone and permeability as a major regulator of local vascular homeostasis. The present study has been designed to investigate the role of endothelium in metabolic disorders.
The endothelium maintains the balance between vasodilatation and vasoconstriction, procoagulant and anticoagulant, prothrombotic and antithrombotic mechanisms.
Diabetes mellitus causes the activation of aldose reductase, polyol pathway and advanced glycation-end-product formation that collectively affect the phosphorylation status and expression of endothelial nitric oxide synthatase (eNOS) and causes vascular endothelium dysfunction. Elevated homocysteine levels have been associated with increase in LDL oxidation, generation of hydrogen peroxides, superoxide anions that increased oxidative degradation of nitric oxide. Hyperhomocysteinemia has been reported to increase the endogenous competitive inhibitors of eNOS viz L-N-monomethyl arginine (L-NMMA) and asymmetric dimethyl arginine (ADMA) that may contribute to vascular endothelial dysfunction. Hypercholesterolemia stimulates oxidation of LDL cholesterol, release of endothelins, and generation of ROS. The increased cholesterol and triglyceride level and decreased protective HDL level, decreases the activity and expression of eNOS and disrupts the integrity of vascular endothelium, due to oxidative stress. Hypertension also stimulates release of endothelins, vasoconstrictor prostanoids, angiotensin II, inflammatory cytokines, xanthine oxidase and, thereby, reduces bioavailability of nitric oxide.
Thus, the cellular and molecular mechanisms underlying diabetes mellitus, hyperhomocysteinemia, hypercholesterolemia hypertension and hyperuricemia leads to an imbalance of phosphorylation and dephosphorylation status of lipid and protein kinase that cause modulation of vascular endothelial L-arginine/nitric oxide synthetase (eNOS), to produce vascular endothelium dysfunction.
血管内皮在营养物质和药物的毛细血管转运中发挥作用,并调节血管生成、稳态以及血管张力和通透性,作为局部血管稳态的主要调节剂。本研究旨在探讨内皮在代谢紊乱中的作用。
内皮维持血管舒张和收缩、促凝和抗凝、促血栓形成和抗血栓形成机制之间的平衡。
糖尿病导致醛糖还原酶、多元醇途径和糖基化终产物形成的激活,这些共同影响内皮型一氧化氮合酶(eNOS)的磷酸化状态和表达,并导致血管内皮功能障碍。同型半胱氨酸水平升高与 LDL 氧化增加、过氧化氢、超氧阴离子生成有关,这些会增加一氧化氮的氧化降解。高同型半胱氨酸血症已被报道会增加内皮型一氧化氮合酶的内源性竞争性抑制剂,如 L-N-单甲基精氨酸(L-NMMA)和非对称二甲基精氨酸(ADMA),这可能导致血管内皮功能障碍。高胆固醇血症刺激 LDL 胆固醇氧化、内皮素释放和 ROS 生成。胆固醇和甘油三酯水平升高,保护性 HDL 水平降低,会降低 eNOS 的活性和表达,并破坏血管内皮的完整性,这是由于氧化应激。高血压还会刺激内皮素、血管收缩性前列腺素、血管紧张素 II、炎性细胞因子、黄嘌呤氧化酶的释放,从而降低一氧化氮的生物利用度。
因此,糖尿病、高同型半胱氨酸血症、高胆固醇血症、高血压和高尿酸血症的细胞和分子机制导致脂质和蛋白激酶的磷酸化和去磷酸化状态失衡,从而调节血管内皮 L-精氨酸/一氧化氮合酶(eNOS),导致血管内皮功能障碍。